45
Participants
Start Date
February 29, 2008
Primary Completion Date
December 31, 2010
Study Completion Date
September 12, 2017
Rituximab
Cycle 1: 100 mg by IV on day 1, 375 mg/m\^2 by IV on day 2 Cycle 2-6: 375 mg/m\^2 by IV on day 1 (every 21 days)
Cyclophosphamide
600 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
Lenalidomide
Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
Pentostatin
2 mg/m\^2 by IV on day 1 of cycles 1-6 (every 21 days)
Mayo Clinic - Jacksonville, Jacksonville
Mayo Clinic Cancer Center, Rochester
Mayo Clinic Scottsdale, Scottsdale
Lead Sponsor
National Cancer Institute (NCI)
NIH
Mayo Clinic
OTHER